Human Coagulation Factor VII Antibody Summary
Ala39-Pro444
Accession # NP_062562
Applications
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Scientific Data
View Larger
Coagulation Factor VII in Human PBMCs. Coagulation Factor VII was detected in immersion fixed PHA-stimulated human peripheral blood mononuclear cells (PBMCs) using 25 µg/mL Mouse Anti-Human Coagulation Factor VII Monoclonal Antibody (Catalog # MAB2338) for 3 hours at room temperature. Cells were stained (red) and counterstained (green). View our protocol for Fluorescent ICC Staining of Non-adherent Cells.
Reconstitution Calculator
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: Coagulation Factor VII
Coagulation Factors VII and VIIa refer to the pro and active forms of the same protease, respectively (1). Factor VII is synthesized in the liver and circulates in the plasma where it binds to tissue factor (TF), an integral membrane protein found in a variety of cell types. Upon binding of TF, Factor VII is rapidly converted into VIIa. The resulting 1:1 complex of VIIa and TF initiates the coagulation pathway and has also important coagulation-independent functions such as angiognesis (2). The cleavage and activation of Coagulation Factors VII, IX and X by VIIa:TF is phospholipid-dependent whereas the cleavage of small peptide substrates is not (1). The predominant splicing variant of Factor VII in normal liver corresponds to the 444 amino acid precursor (3, 4). After a signal peptide (aa 1 to 38), the mature chain can be further processed into the light chain (aa 39 to 190) and the heavy chain (aa 191 to 444).
- Morrissey, J.H. (2004) in Handbook of Proteolytic Enzymes, Barrett, A.J. et al. eds. p. 1659.
- Versteeg, H.H. et al. (2003) Carcinogenesis 24:1009.
- Hagen, F.S, et al. (1986) Proc. Natl. Acad. Sci. USA 83:2412.
- O’Hara, P.J. et al. (1987) Proc. Natl. Acad. Sci. USA 84:5158.
Product Datasheets
Citation for Human Coagulation Factor VII Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
1 Citation: Showing 1 - 1
-
Factor VII light chain-targeted lidamycin targets tissue factor-overexpressing tumor cells for cancer therapy
Authors: Qing Zhang, Xiu-Jun Liu, Lian Hu, Dong-Sheng Liao, Yan-Bo Zheng, Yong-Su Zhen et al.
International Journal of Molecular Medicine
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsReviews for Human Coagulation Factor VII Antibody
There are currently no reviews for this product. Be the first to review Human Coagulation Factor VII Antibody and earn rewards!
Have you used Human Coagulation Factor VII Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
